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Introduction

20
Skin is a natural barrier yet, for many years has been a desirable route of administration for 21 therapeutic drugs. For any cosmetic skincare product, environmental, or pharmaceutical compound, it 22 is vital to know both the rate, and extent, of transdermal permeation to satisfy regulatory authorities.
23
There are several ways the required data can be acquired, broadly categorized into in vivo, ex vivo and 24 in vitro models (1). For all products that are intended for percutaneous permeation the main intention 25 is optimisation of the drug and formulation to achieve maximum in vivo performance. Ideally, human 26 studies would be undertaken to ascertain such information. However, this is not normally feasible 27 during development. Thus, researchers resort to the aforementioned models. Until recent years, the 28 majority of studies in this area utilised a wide variety of animals, mainly rodents (2), to obtain drug 29 permeation data which can then be used as a basis to predict clinical outcomes. Although the volume 30 of data that has arisen from such in vivo work has been beneficial in the development of some 31 pharmaceutical products, there is a clear trend to move away from animal studies (3) for three main 32 reasons. Firstly, ethical issues surrounding the use of live animals is a major incentive to consider 33 other testing methods. This is especially true in the EU and several other markets where it is already 34 no longer permissible for cosmetic product testing to involve the use of animals, with further 35 restrictions to follow (4). Although their use in the pharmaceutical industry is still permissible, there is 36 a clear move towards avoiding animal studies where possible. Secondly, researchers are adopting skin 37 mimic systems because the animal study data that does exist cannot easily be compared and analysed 38 across experimental studies as a result of the diverse range of animals used in research. Even within 39 datasets from similar species the results may vary so considerably that comparative analysis is 40 impossible, even within human studies inter-individual variation can be an issue (5, 6). The third, and 41 possibly the most compelling, reason that transdermal permeation studies may avoid the use of 42 animals is a lack of clear correlation between animal and human clinical trial data. For example, it has 43 been shown that rodent skin generally shows higher permeation rates than human skin, often leading 44 to incorrect conclusions from experimental data (7). Porcine skin, particularly that from the ear, is 45 used in permeation studies as it has been shown to have similar properties to human skin (8) yet full 46 animal studies with pigs are not ideal for the reasons previously outlined. 47
The outermost layer of human skin is the stratum corneum and is the main barrier for 48 transdermal permeation. In human stratum corneum, the major lipid classes are ceramides, cholesterol 49 and saturated long chain free fatty acids (9). Lipid organisation is fundamental to skin barrier 50 function, for example in diseased or dry skin the lipid composition is different from that in healthy 51 subjects. However, the specific details regarding lipid organisation within the stratum corneum are not 52 fully understood, although it is accepted they will have an influence on transdermal permeation (10).
53
It should be noted that in some cases it is not transdermal permeation that is desired but dermal 54 absorption, i.e. delivery within particular regions of the skin itself -see ref.
(11-13) for examples. In 55 such circumstances transdermal permeation must still be measured, and considered, to satisfy 56 regulators regardless of whether permeation is the intended outcome or not. For dermal delivery 57 studies, drug permeation and distribution is not as specifically focused on the stratum corneum 58 permeation as transdermal studies, but will also consider the deeper layers individually, namely viable 59 epidermis and dermis. These are not so relevant to transdermal research as it is often assumed that 60 stratum corneum penetration is the rate limiting step in permeation and must therefore be the focus of 61 such studies. 62
Skin permeability is closely linked with the hydrophobicity/hydrophilicity of the molecule in 63 question. In general, researchers have shown that skin permeability decreases with increasing 64 hydrophilicity, as expected based on the lipidic structure of the skin (14 Investigations into the formulation aspects of the applied product have further confirmed the 170 variability that can occur as a result of modifications in the chemical nature of the excipients selected 171 (36-41). For example, research within our own group has found substantial effects based upon the 172 simple addition of an anionic surfactant to the formulation, yet no effect upon the addition of a 173 cationic surfactant (37). For example, a study into the influence of ethanol on the solubility, ionisation 174 and permeation characteristics of a model drug (ibuprofen) found the flux through silicone 175 membranes increased up to a maximum of 100 % ethanol yet, in human skin, flux was optimal at 176 lower ethanol percentages (42). Following on from this study, researchers investigated the influence 177 of propylene glycol (PG) using binary (PG:water) and ternary (ethanol:PG:water) solvent systems.
178
Fluxes were maximum for 70:30 PG:water systems in silicone membrane; however, for experiments 179 conducted with skin, the flux of ibuprofen systematically increased with increasing amounts of PG. is best to choose one with high porosity, a tortuosity of one and be relatively thin. Furthermore, the 206 compatibility of the membrane with the donor, and receptor, components must be considered, along 207 with the cost effectiveness of the membrane. In transdermal permeation studies, it is common to 208 measure drug release rates by monitoring the cumulative mass of drug appearing in the receptor 209 solution (M R ). However, if a synthetic membrane is placed between the donor and receptor phases 210 then there is a delay in drug transfer, and M R is not immediately linear with respect to time. As a result 211 of this non-linearity it is vital that permeation studies are conducted for long enough that the 212 relationship achieves linearity to ensure calculated drug diffusivity values are correct (48). 213
More complex synthetic membranes have shown promise to provide a better representation of 214 the stratum corneum barrier, for example, using a polydimethylsiloxane-polycarbonate block 215 copolymer membrane (Carbosil) (49). In one such study, permeability was examined as a function of 216 permeant molecular weight, melting point, solubility, partition coefficient and diffusivity for 14 drugs 217 covering a wide range of chemical structures. It was found that Carbosil provided a higher drug 218 solubility, and consequently, higher permeability compared with human skin. However, by varying 219 the block copolymer membrane the diffusivity could be significantly modified, implying a more 220 appropriate in vivo model can be created. Further work in this field has led researchers to establish the 221 importance of considering membrane hydration in such studies (50). In another study two synthetic 222 lipid models (designed to replace human stratum corneum) were studied to investigate the impact of 223 volatile organic chemicals on the molecular organization of the skin barrier lipids (51). The models 224 built upon previously developed self-assembled lipid membranes, which have a composition and 3D 225 organisation similar to those of the in vivo lipid matrix. In one model the target chemicals were 226 incorporated in the lipids before their self-assembly, and in the other one they were applied on top of a 227 preformed lipid membrane. Encouragingly, the dose-dependent effects of the chemicals on the lateral 228 molecular organization in the models were qualitatively identical to those observed by infrared 229 spectroscopy in human skin. The study concluded that these model systems are suitable for in vitro 230 studies in the areas of skin biophysics, dermatology, transdermal drug delivery, and risk assessment. 231 Natural membranes have also been considered to measure permeation for model drugs, 232 including those of different molecular weights and lipophilicities using Franz-type diffusion cells. For 233 example, membranes can be taken from the outer layers of peach and tomato, the middle layers of 234 onions and with the inner layer of eggs (52). Encouragingly, results showed that the rate and amount 235 of diclofenac permeated through onion skin, metronidazole through tomato skin and erythromycin 236 through egg membrane was not significantly different from that with human skin. From these results 237 it was concluded that natural membranes have pores and channels with hydrophilic properties, 238 permitting permeation of small to middle size hydrophilic drugs to diffuse in a manner similar to 239 human skin. Other natural membranes have also been considered for transdermal studies, and 240 comparisons made with the more standard membrane options (53). 241
Within the last ten years a parallel artificial membrane permeability assay (PAMPA) has been 242 developed for the rapid determination of passive transport permeability in vitro, gaining acceptance in 243 pharmaceutical research. In PAMPA, a 96-well filter plate coated with a liquid artificial membrane is 244 used to separate two compartments: one containing a buffer solution of compounds to be tested 245 (defined as donor compartment) and the other containing an initial fresh buffer solution (defined as 246 acceptor compartment). In one of the earliest studies, isopropyl myristate, silicone oil, and mixtures of 247 the two components were immobilised on filters and tested as liquid supported membranes in 248 PAMPA to evaluate their potential to mimic the human skin barrier (54). Effective permeability 249 coefficients (P e ) were determined for a set of compounds using the PAMPA technique and compared 250 with the corresponding human skin permeability coefficient values (K p ). A good correlation between 251 P e and K p was found for compounds tested through a membrane consisting of 70 % silicone and 30 % 252 IPM. Moreover, a positive correlation between the membrane retention of compounds and stratum 253 corneum/water partition coefficients (P SC ) was established, implying PAMPA can be used for the 254 prediction of passive human skin permeability coefficients. Further studies in this area have further 255 confirmed the validity of the technique (55) and, along with the low cost, versatility and good 256 reproducibility (56) of the system ensure it is a feasible membrane mimic system. In 2012, Sinko et al.
257
(57) attempted to match the permeability of the rate-limiting barrier in human skin using synthetic 258 analogs of the ceramides present in the stratum corneum. The final skin-PAMPA membrane lipid 259 mixture (certramide, free fatty acid, and cholesterol) was selected and optimized based on data from 260 three different human skin databases and the final model was found to correlate well to all of the 261 databases. The reproducibility of the skin-PAMPA model was investigated and compared to that of 262 other PAMPA models, confirming it to be a quick and cost-effective research tool that can serve as a 263 useful model of skin penetration in pharmaceutical and cosmetic research. More recently, several 264 variations of the artificial membrane employed in the PAMPA study system were analysed (isopropyl 265 myristate (IPM), certramides and Strat-M™) (58). These were evaluated for their ability to predict the 266 skin permeability of caffeine, cortisone, diclofenac sodium, mannitol, salicylic acid and testosterone 267 applied in propylene glycol, water and ethanol as unsaturated and saturated concentrations. Resultant 268 absorption data was compared to skin diffusion cell data. The correlations between membrane and 269 diffusion cell data from saturated and unsaturated concentrations were rather low, although this 270 relationship improved when only saturated concentrations were evaluated. These results suggest the 271 potential of PAMPA as an initial screening approach to assist in narrowing the selection of 272 formulations to be evaluated, thereby assisting in the development of new topical formulations. Based 273 on these findings and others in the field (59), PAMPA has been accepted as a suitable skin mimic 274 system that can provide significant benefits for in vitro analysis compared with more simplistic 275 artificial membrane systems. Furthermore, results of PAMPA permeability and retention have been 276 used to create mathematical models that could be employed for the design of novel derivatives with a 277 favorable skin retention/permeability ratio. 278
In summary, in vitro models for predicting transdermal permeation have been thoroughly 279 studied over the years, including the effects of factors such as the formulation and choice of 280 membrane system. In recent years, researchers have successfully developed more complex artificial 281 membrane systems that are able to provide precise and accurate predictions of transdermal permeation 282 without the need to use human or animal skin. The benefits of such non-in vivo systems are 283 significant, for economic, reproducibility and ethical reasons amongst others. 284
285
Mathematical models including quantitative structure-permeability relationships (QSPRs) 286
Using models to predict the permeability of a compound through skin is particularly complex 287 as a result of the intricate nature of the structures and mechanisms that dictate the delivery pathway.
288
While the stratum corneum barrier, which serves as the major rate-limiting component to skin 289 penetration for most drugs, has been the focus of most penetration models, much less is known about 290 transport beyond this stage, and about transport via the appendageal routes. When modelling skin 291 transport processes quantitatively, it is usual to consider the particular physiological regions of 292 interest as compartments (60). Drug levels within the compartments can be modelled as a single time-293 dependent value, or as function of both position within that compartment (usually skin depth) as well 294 as time. For the latter choice, drug transport within the compartment may be modelled using partial 295 differential equations that describe the effects of drug diffusion, convection, elimination and 296 metabolism (61). Models usually concern the steady-state flux of drug into the skin and related 297 quantities such as the permeability coefficient and the maximum steady-state flux, the lag time 298
between drug application and attainment of the steady state; the clearance of drug through excretion; 299 and drug concentrations in the various skin layers, circulation, or other tissues (62). Theoretical 300 permeation models have become more and more complex over the past fifty years. For example, 301
ranging from simple models that consider the stratum corneum as a single compartment to those more 302 complex that consider the structural characteristics of skin, including contributions from the lipidic 303 components. Complexity may not always be necessary, for example, one particular study in 2011 304 found that only by using a two-compartment dermal clearance model that includes both diffusion and 305 transport by dermal blood vessels consistency was obtained between observed and previously 306 described in vivo literature data (63). 307
In general, two types of mathematical models have been developed to predict transdermal 308 permeation, i.e. those based on the properties of the compound permeating or those based on the 309 properties of the skin being permeated. Whereas the first is focused on predicting penetration through 310 the skin from a solute's physicochemical properties, the second type models transport processes in 311 skin layers using appropriate equations with the specific aim of predicting the concentration of a given 312 solute in viable skin tissues (64). In general, it has been found that models are an important tool for 313 accurate valuation of skin toxicity experiments, estimation of skin toxicity and for developing new 314 formulations for skin disease therapy. Being aware of toxicological responses is important for a 315 variety of reasons, for example when considering likely exposure of workers to certain compounds 316 (65, 66). However, more comprehensive mathematical models of drug transport in skin, especially 317 those based on more physiologically detailed mechanistic considerations of transport processes, are 318 required to further enhance their role in assessing skin toxicology. 319
Models of skin absorption have attracted significant interest in the last two decades following 320 the publication of two models for quantitative analysis (67, 68) in which permeability was related to 321 physicochemical properties of the permeant. Prior to that, the majority of studies tended to focus on 322 only small groups of compounds and the relationship with hydrophobicity where, unsurprisingly, it 323 was found an increase in hydrophobicity led to an increase in permeation. Expanding consideration to 324 a wider range of permeant characteristics, for example hydrogen bonding, melting point and 325 ionization properties, led to the development of more 'refined' models, summarized in references (35) 326 and (69). 327
Fitting experimental data to create statistically derived equations creates quantitative 328 structure-permeability relationship (QSPR) models. Most QSPR models consider skin permeation 329 through tortuous lipid pathways that may under-predict skin permeability of hydrophilic solutes, by 330 several orders of magnitude. As a result of this researchers have begun, in recent years, to consider 331 including aqueous pathways to improve the predictive abilities of permeation for hydrophilic solutes 332 (70). As a further complication, some compounds are known to undergo metabolism within the skin 333 thus several models also take into account contributions from metabolite permeation (71). As a variety 334 of physicochemical parameters are known to potentially impact on drug-release profiles, researchers 335 have developed mathematical models that take such parameters into account, for example taking into 336 consideration the effects of dosing level, the type of vehicle (i.e. formulation), concentration profiles 337 (72), solubility in particular solvents (73) and ionisation state of the permeant (74). Although these 338 models tend to be based on several assumptions (for example: that steady-state transport across the 339 skin is achieved even though a finite dose was applied) they have been shown to be successful for 340 predictive ability in certain situations. Combining calculations of skin concentrations within two 341 diffusion layers and results from silicone membrane permeations studies has led to precise predictions 342 of in-skin concentrations (75). A few studies have evaluated the correlation between skin permeability 343 predictive models and human in vivo data, with mixed findings, ranging from one study concluding 344 most models correlated well with the in vivo data (76), through to another study that declared models 345
were not suitable for accurately predicting permeation but were able to effectively rank the permeants 346 and could help to select candidate molecules for in vitro screening (77). 347
In summary, mathematical models of transdermal permeation play an essential role in the 348 investigation of epidermal and dermal transport of compounds, despite their limitations based on 349 assumptions introduced to simplify the process, they are useful tools for data analysis, and predictions 350 for dermal solute penetration (78). 351
352
Human skin equivalent models 353
As researchers have strived to create an in vitro model as close as possible to human skin, 354 many have viewed the development of three dimensional tissue models to be the ultimate goal. A 355 major drive towards this aim has arisen from the cosmetic industry with the necessity to replace 356 animal testing therefore creating a regulatory reason to provide human skin equivalents. This research 357 is now beginning to be adopted by pharmaceutical scientists as applications for measuring transdermal 358 permeation are realised. Although attempts have been made to produce a reliable model for over 359 twenty years, as recently as 2001 there was a belief that such models were not useful for in vitro 360 penetration studies compared with other existing methods. For example, one particular study found far 361 higher flux and skin concentration values using a living skin equivalent compared with human skin 362 (79). However, more recently, human skin equivalents have been described as an 'excellent' tool, for 363 example to study water distribution following application of moisturiser (80), and many view them as 364 the future of transdermal permeation studies in vitro (81-85). 365
Models formed using only one cell type, known as reconstructed human epidermis (RHE), are 366 used for their high level of reproducibility, yet can be viewed as too simplistic for consideration as a 367 complete human skin equivalent system. The European Centre for the Validation of Alternative 368
Methods has validated several RHE models for skin corrosion and irritancy studies confirming their 369 place as a viable replacement to other methods to obtain such data. To conform to the necessary 370 criteria the test systems must pass minimum standards relating to viability, barrier function, 371 morphology, reproducibility and quality control. Analytical techniques to verify these criteria include 372 infrared and Raman spectroscopy (86) and confocal laser scanning microscopy (87). Researchers 373 have attempted to apply RHE models to determine drug permeation and one such study found values 374 exceeded those for human epidermis yet, showed a tendency towards a lower level of variability (88). 375
Commercially available examples include SkinEthic ® Rhe and Episkin ® , both developed by L'Oreal, 376
France and more recently, oral epithelium models such as EpiOral™ (MatTek Corporation, USA). 377
Full thickness models consist of more complex systems, for example incorporating additional 378 cell types such as melanocytes and stem cells. By increasing the complexity of the models, through 379 incorporation of additional components, researchers believe they more truly replicate in vivo scenarios 380 yet it must also be remembered they decrease the reproducibility and can significantly increase 381 experimental costs. A detailed summary of the available state-of-the-art models can be found in 382 reference (89). Full thickness models are composed of both dermal and epidermal layers, i.e. creating 383 a bilayer structure similar to that found in human skin. More and more complex systems are 384 continually being created, such as by the creation of a viable adipose layer (90), allowing researchers 385 to resolve more complex dermatological issues (91). Commercially available examples include 386 RealSkin ® (L'Oreal, France) and AST2000 (CellSystems Biotechnologie GmbH, Germany) (92). 387
Unsurprisingly, there are limitations even with three dimensional skin models which must be 388 addressed when considering the use of such systems for in vitro permeation determination. Firstly, 389 most relevant to cosmetic applications, is the inability of the models to generate stratum corneum, as 390 they consist of primary cells with a limited lifespan and, a lack of cells of the immune system. It has 391 been proposed that immortalised cell lines could improve the reproducibility and consistency of skin 392 models reducing intra and inter-laboratory variations (93). Secondly, some studies have reported a 393 dissimilar barrier function of human skin equivalents. For example, one such study found that the 394 models were able to mimic many aspects of human skin but, differed in their barrier properties (94), 395 implying they would not be suitable for permeation studies. Finally, the limited lifespan of these 396 living models (~ eight weeks), reduces their suitability for experimental study, although some work 397 has been conducted in this area to improve this situation, in one case increasing their availability for 398 up to twenty weeks (95) . 399 With such a rapid expansion of work (and commercially available products) in this area it is 400 inevitable that the future of skin mimic systems incorporates aspects of RHE or full thickness models 401 to some extent. 402
403
Chromatographic models 404
High-performance liquid chromatography (HPLC) has been utilised and adapted to predict 405 skin permeability data, mainly in the last twenty years. Recently, the ability of a selection of 406 chromatographic systems to model human skin permeation has been evaluated and tested, by 407 correlating experimental data with in vivo data for a representative set of neutral solutes (96). It was 408 reported for the six systems (including the classic octanol-water partition system) that the HPLC 409 systems with C18 columns are the closest to the human skin permeation system whereas the micellar 410 electrokinetic chromatographic (MEKC) systems were most different -based on distance parameters. 411
However, the study also declared that error arising from the original skin permeability data is quite 412 significant and the variance from the C18 systems was possibly too high to provide precise research group has developed, evaluated and published a method to measure the chromatographic 439 retention of drugs which can then be used to predict skin permeability using micellar chromatography, 440 achieving high levels of reliability (104). In our study, we looked at a series of model compounds and 441
found that the replacement of a traditional physicochemical parameter, namely the octanol-water 442 partition coefficient, with a chromatographically determined value resulted in a quantitative value that 443 was robust to variation, i.e. a suitable method to predict transdermal permeation. The advantages of 444 this method are numerous, and of particular benefit is the high level of predictive capability that has 445 not been seen in other studies. 446
In summary, chromatographic methods appear to show promise using a variety of 447 experimental conditions and, may make a positive contribution to the future prediction of transdermal 448 permeation. 449
450
Conclusions 451
When undertaking a study to investigate transdermal permeability, there are many options to 452 consider, and researchers tend to choose techniques that are most suited to their intended purpose, 453 availability, previous experience or economic constraints. The majority of the techniques currently 454 available have been shown to be suitable for ranking a series of compounds (or formulations), yet do 455 not provide an in vitro-in vivo correlation that suggests they can be used as a pure replacement. For 456 many reasons this is the ultimate aim of such studies and work continues to develop systems that can 457 either mimic skin to permit experimental data to be measured (i.e. using synthetic membranes or 458 human skin equivalents), or predict permeation (i.e. using chromatographic methods or mathematical 459 models). Development of the latter will undoubtedly lead to the availability of software that can 460 simulate absorption of dose into the skin, diffusion through the skin and clearance into blood which 461 can be used in the development of pharmaceuticals, cosmetics, household products and 462 agrochemicals. A very limited number of such packages are already available, such as the Skin-in-463
Silico™ software (Xemet, Finland), yet it is highly anticipated that this is the likely direction of 464 transdermal studies in the future, thus completely replacing the need for animal testing. Clearly, it can 465 be seen that only through understanding the physicochemical properties of the compound under 466 investigation and the structure of the skin is it possible to quantify transdermal permeation. 
